1. Market Research
  2. > Healthcare
  3. > Pathology Market Trends
  4. > Auto Inflammatory Disease – Pipeline Review, H1 2013

Auto Inflammatory Disease – Pipeline Review, H1 2013

  • May 2013
  • -
  • Global Markets Direct
  • -
  • 42 pages

Auto Inflammatory Disease – Pipeline Review, H1 2013

Summary

Global Markets Direct’s, 'Auto Inflammatory Disease - Pipeline Review, H1 2013', provides an overview of the indication’s therapeutic pipeline. This report provides information on the therapeutic development for Auto Inflammatory Disease, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Auto Inflammatory Disease. Auto Inflammatory Disease - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- A snapshot of the global therapeutic scenario for Auto Inflammatory Disease.
- A review of the Auto Inflammatory Disease products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the Auto Inflammatory Disease pipeline on the basis of route of administration and molecule type.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.

Reasons to buy

- Identify and understand important and diverse types of therapeutics under development for Auto Inflammatory Disease.
- Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
- Plan mergers and acquisitions effectively by identifying players of the most promising pipeline.
- Devise corrective measures for pipeline projects by understanding Auto Inflammatory Disease pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.

Table Of Contents

Auto Inflammatory Disease - Pipeline Review, H1 2013
Table of Contents

Table of Contents 2
List of Tables 4
List of Figures 4
Introduction 5
Global Markets Direct Report Coverage 5
Auto Inflammatory Disease Overview 6
Therapeutics Development 7
An Overview of Pipeline Products for Auto Inflammatory Disease 7
Auto Inflammatory Disease Therapeutics under Development by Companies 9
Auto Inflammatory Disease Therapeutics under Investigation by Universities/Institutes 10
Late Stage Products 11
Comparative Analysis 11
Discovery and Pre-Clinical Stage Products 12
Comparative Analysis 12
Auto Inflammatory Disease Therapeutics - Products under Development by Companies 13
Auto Inflammatory Disease Therapeutics - Products under Investigation by Universities/Institutes 14
Companies Involved in Auto Inflammatory Disease Therapeutics Development 15
Emergent BioSolutions Inc. 15
Biovitrum AB 16
Alba Therapeutics Corporation 17
Auto Inflammatory Disease - Therapeutics Assessment 18
Assessment by Monotherapy Products 18
Assessment by Route of Administration 19
Assessment by Molecule Type 21
Drug Profiles 23
anakinra - Drug Profile 23
Product Description 23
Mechanism of Action 23
RandD Progress 23
AT-1004 Vaccine Adjuvants - Drug Profile 24
Product Description 24
Mechanism of Action 24
RandD Progress 24
ES-301 - Drug Profile 25
Product Description 25
Mechanism of Action 25
RandD Progress 25
Permeability Inhibitor Candidates - Drug Profile 26
Product Description 26
Mechanism of Action 26
RandD Progress 26
Permeability Inducer Candidates - Drug Profile 27
Product Description 27
Mechanism of Action 27
RandD Progress 27
SEL-212 Program - Drug Profile 28
Product Description 28
Mechanism of Action 28
RandD Progress 28
Cot/Tpl-2 Inhibitor - Drug Profile 29
Product Description 29
Mechanism of Action 29
RandD Progress 29
Auto Inflammatory Disease Therapeutics - Drug Profile Updates 30
Auto Inflammatory Disease Therapeutics - Dormant Products 31
Auto Inflammatory Disease - Product Development Milestones 32
Featured News and Press Releases 32
Nov 19, 2012: Sobi Files To Expand Kineret Label To Include CAPS 32
Nov 11, 2012: Novartis' Phase II Data Show ACZ885 Delivered Rapid And Strong Symptom Relief While Reducing Frequency Of Attacks In Two Periodic Fever Syndromes 32
Sep 06, 2012: Generon Initiates Phase I Clinical Study For F-652 In Australia 34
Jun 06, 2012: Novartis Announces New Data From Two Trials Of ACZ885 At Annual Congress Of EULAR 2012 35
Sep 27, 2011: Novartis Receives Approval For Ilaris In Japan For Cryopyrin-Associated Periodic Syndrome 37
Sep 27, 2011: Novartis Receives Approval For Ilaris In Japan For Cryopyrin-Associated Periodic Syndrome 37
Jul 12, 2011: AnaptysBio Selects Anti-IL17 mAb Development Candidate To Treat Autoimmune And Inflammatory Conditions 38
Jun 23, 2011: Avila Presents Preclinical Data Of AVL-292 Demonstrating Suppression Of Autoimmune Disease Activity 38
Aug 26, 2010: Swedish Orphan Biovitrum Receives FDA Orphan Drug Designation For Kineret 39
May 13, 2008: ChemoCentryx Initiates Clinical Trial Of CCX354 For The Treatment Of Inflammatory Disease 39
Appendix 41
Methodology 41
Coverage 41
Secondary Research 41
Primary Research 41
Expert Panel Validation 41
Contact Us 42
Disclaimer 42



List of Tables

Number of Products Under Development for Auto Inflammatory Disease, H1 2013 7
Products under Development for Auto Inflammatory Disease - Comparative Analysis, H1 2013 8
Number of Products under Development by Companies, H1 2013 9
Number of Products under Investigation by Universities/Institutes, H1 2013 10
Comparative Analysis by Late Stage Development, H1 2013 11
Comparative Analysis by Discovery and Pre-Clinical Stage Development, H1 2013 12
Products under Development by Companies, H1 2013 13
Products under Investigation by Universities/Institutes, H1 2013 14
Emergent BioSolutions Inc., H1 2013 15
Biovitrum AB, H1 2013 16
Alba Therapeutics Corporation, H1 2013 17
Assessment by Monotherapy Products, H1 2013 18
Assessment by Stage and Route of Administration, H1 2013 20
Assessment by Stage and Molecule Type, H1 2013 22
Auto Inflammatory Disease Therapeutics - Drug Profile Updates 30
Auto Inflammatory Disease Therapeutics - Dormant Products 31



List of Figures

Number of Products under Development for Auto Inflammatory Disease, H1 2013 7
Products under Development for Auto Inflammatory Disease - Comparative Analysis, H1 2013 8
Products under Development by Companies, H1 2013 9
Products under Investigation by Universities/Institutes, H1 2013 10
Late Stage Products, H1 2013 11
Discovery and Pre-Clinical Stage Products, H1 2013 12
Assessment by Monotherapy Products, H1 2013 18
Assessment by Route of Administration, H1 2013 19
Assessment by Stage and Route of Administration, H1 2013 20
Assessment by Molecule Type, H1 2013 21
Assessment by Stage and Molecule Type, H1 2013 22

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Veronica

+1 718 514 2762

Purchase Reports From Reputable Market Research Publishers
Diabetes & Obesity Drug Development Pipeline Review, 2016

Diabetes & Obesity Drug Development Pipeline Review, 2016

  • $ 3995
  • Company report
  • December 2016
  • by GBI Research

Diabetes & Obesity Drug Development Pipeline Review, 2016 Summary The diabetes and obesity disease cluster is currently dominated by therapeutics indicated for type 1 diabetes mellitus (T1DM) and type ...

Ophthalmology Drug Development Pipeline Review, 2016

Ophthalmology Drug Development Pipeline Review, 2016

  • $ 3995
  • Company report
  • December 2016
  • by GBI Research

Ophthalmology Drug Development Pipeline Review, 2016 Summary Ophthalmology disorders are associated with the eyes and visual system. If left untreated, serious long-term co-morbidities such as diabetes, ...

A Disintegrin And Metalloproteinase With Thrombospondin Motifs 5 (A Disintegrin And Metalloproteinase With Thrombospondin Motifs 11 or Aggrecanase 2 or ADMP2 or ADAMTS5 or EC 3.4.24.) - Pipeline Review, H2 2016

A Disintegrin And Metalloproteinase With Thrombospondin Motifs 5 (A Disintegrin And Metalloproteinase With Thrombospondin Motifs 11 or Aggrecanase 2 or ADMP2 or ADAMTS5 or EC 3.4.24.) - Pipeline Review, H2 2016

  • $ 3500
  • Company report
  • August 2016
  • by Global Markets Direct

A Disintegrin And Metalloproteinase With Thrombospondin Motifs 5 (A Disintegrin And Metalloproteinase With Thrombospondin Motifs 11 or Aggrecanase 2 or ADMP2 or ADAMTS5 or EC 3.4.24.) - Pipeline Review, ...


ref:plp2013

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.